Synergy between amyloid-β and tau in Alzheimer's disease
Patients with Alzheimer's disease (AD) present with both extracellular amyloid-β (Aβ)
plaques and intracellular tau-containing neurofibrillary tangles in the brain. For many years …
plaques and intracellular tau-containing neurofibrillary tangles in the brain. For many years …
[HTML][HTML] Inflammation context in Alzheimer's disease, a relationship intricate to define
C Novoa, P Salazar, P Cisternas, C Gherardelli… - Biological Research, 2022 - Springer
Abstract Alzheimer's disease (AD), the most common form of dementia, is characterized by
the accumulation of amyloid β (Aβ) and hyperphosphorylated tau protein aggregates …
the accumulation of amyloid β (Aβ) and hyperphosphorylated tau protein aggregates …
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease
Alzheimer's disease (AD) causes unrelenting, progressive cognitive impairments, but its
course is heterogeneous, with a broad range of rates of cognitive decline. The spread of tau …
course is heterogeneous, with a broad range of rates of cognitive decline. The spread of tau …
[HTML][HTML] Neuroprotective effects of coffee bioactive compounds: a review
K Socała, A Szopa, A Serefko, E Poleszak… - International journal of …, 2020 - mdpi.com
Coffee is one of the most widely consumed beverages worldwide. It is usually identified as a
stimulant because of a high content of caffeine. However, caffeine is not the only coffee …
stimulant because of a high content of caffeine. However, caffeine is not the only coffee …
Network abnormalities and interneuron dysfunction in Alzheimer disease
The function of neural circuits and networks can be controlled, in part, by modulating the
synchrony of their components' activities. Network hypersynchrony and altered oscillatory …
synchrony of their components' activities. Network hypersynchrony and altered oscillatory …
Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer's disease susceptibility
Here we use deep sequencing to identify sources of variation in mRNA splicing in the
dorsolateral prefrontal cortex (DLPFC) of 450 subjects from two aging cohorts. Hundreds of …
dorsolateral prefrontal cortex (DLPFC) of 450 subjects from two aging cohorts. Hundreds of …
[HTML][HTML] Defining imaging biomarker cut points for brain aging and Alzheimer's disease
CR Jack Jr, HJ Wiste, SD Weigand, TM Therneau… - Alzheimer's & …, 2017 - Elsevier
Introduction Our goal was to develop cut points for amyloid positron emission tomography
(PET), tau PET, flouro-deoxyglucose (FDG) PET, and MRI cortical thickness. Methods We …
(PET), tau PET, flouro-deoxyglucose (FDG) PET, and MRI cortical thickness. Methods We …
A review on advances of treatment modalities for Alzheimer's disease
Alzheimer's disease (AD) is a multifactorial neurodegenerative disease which is mainly
characterized by progressive impairment in cognition, emotion, language and memory in …
characterized by progressive impairment in cognition, emotion, language and memory in …
[HTML][HTML] Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers
Current technological advancements in clinical and research settings have permitted a more
intensive and comprehensive understanding of Alzheimer's disease (AD). This development …
intensive and comprehensive understanding of Alzheimer's disease (AD). This development …
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
Alzheimer's disease (AD) is characterized by two molecular pathologies: cerebral β-
amyloidosis in the form of β-amyloid (Aβ) plaques and tauopathy in the form of neurofibrillary …
amyloidosis in the form of β-amyloid (Aβ) plaques and tauopathy in the form of neurofibrillary …